Cancer Center Member Publications and Abstracts Site

Latticegrid
Powered by LatticeGrid

Adam Matthew Petrich, MDEdit profile     Publications     Word cloud      
Visualizations: Radial1     Radial2     Spring     Wheel     Chord     Tree     Awards     Studies    
Graph of all data     Reports: Awards     Studies     MeSH: similarities graph    
Academic TitleAssistant Professor
DepartmentMedicine, Hematology Oncology Division; Feinberg School of Medicine
AffiliationsHematologic Malignancies (Member)
CampusChicago
AddressGALTER 676 N St Clair St 8th flr CH HNMH
Email
Description The focus of Dr. Petrich's research is on the use of novel drugs and drug combinations for the treatment of lymphomas. His laboratory research has focused on exploring epigenomic differences that account for differences is response of lymphoma cells to chemotherapy. His research has focused specifically on the Akt/mTOR pathway, with the hopes that more effective targeting of molecules in this pathway may lead to improved outcome in certain types of non-Hodgkin lymphoma. He is the local principal investigator of a number of clinical trials, and is actively recruiting patients to the many active trials available here at Northwestern.
InterestsNon-Hodgkin lymphoma (including diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma), AIDS-related lymphoma, post-transplant lymphoproliferative disorder, Hodgkin lymphoma.
PubMed IDs
Show ➲

Publications (19)

Publications
Evens, A. M.; Kanakry, J. A.; Sehn, L. H.; Kritharis, A.; Feldman, T.; Kroll, A.; Gascoyne, R. D.; Abramson, J. S.; Petrich, A. M.; Hernandez-Ilizaliturri, F. J.; Al-Mansour, Z.; Adeimy, C.; Hemminger, J.; Bartlett, N. L.; Mato, A.; Caimi, P. F.; Advani, R. H.; Klein, A. K.; Nabhan, C.; Smith, S. M.; Fabregas, J. C.; Lossos, I. S.; Press, O. W.; Fenske, T. S.; Friedberg, J. W.; Vose, J. M.; Blum, K. A. Gray zone lymphoma with features intermediate between classical hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.Am J Hematol (2015) 90:778-783. 26044261; 10.1002/ajh.24082
Frankfurt, O.; Ma, S.; Gordon, L.; Winter, J. N.; Horowitz, J.; Rademaker, A.; Weitner, B. B.; Peterson, L. C.; Altman, J. K.; Tallman, M. S.; Petrich, A.; Rosen, S. T. A Phase II Study of Alemtuzumab-Rituximab Therapy in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Short and Long-term Outcomes.Leuk Lymphoma (2015) 56:315-323. 24707943; 10.3109/10428194.2014.910654
Petrich, A. M.; Helenowski, I. B.; Bryan, L. J.; Rozell, S. A.; Galamaga, R.; Nabhan, C. Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era.Br J Haematol (2015) 168:708-718. 25382108; 10.1111/bjh.13202
Devita, M. D.; Evens, A. M.; Rosen, S. T.; Greenberger, P. A.; Petrich, A. M. Multiple successful desensitizations to brentuximab vedotin: a case report and literature review.J Natl Compr Canc Netw (2014) 12:465-471. 24717566
Gandhi, M. D.; Evens, A. M.; Fenske, T. S.; Hamlin, P.; Coiffier, B.; Engert, A.; Moskowitz, A. J.; Ghosh, N.; Petrich, A. M.; Lomasney, J.; Chadburn, A.; Wood, G. S.; Salva, K.; Nardone, B.; Trifilio, S. M.; Raisch, D. W.; West, D. P.; Gordon, L. I.; Winter, J. N. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.Blood (2014) 123:2895-2897. 24786458; PMC4007615; 10.1182/blood-2014-03-561878
Gentzler, R. D.; Evens, A. M.; Rademaker, A. W.; Weitner, B. B.; Mittal, B. B.; Dillehay, G. L.; Petrich, A. M.; Altman, J. K.; Frankfurt, O.; Variakojis, D.; Singhal, S.; Mehta, J.; Williams, S.; Kaminer, L.; Gordon, L. I.; Winter, J. N. F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.Br J Haematol (2014) 165:793-800. 24628515; 10.1111/bjh.12824
Petrich, A. M.; Gandhi, M.; Jovanovic, B.; Castillo, J. J.; Rajguru, S.; Yang, D. T.; Shah, K. A.; Whyman, J. D.; Lansigan, F.; Hernandez-Ilizaliturri, F. J.; Lee, L. X.; Barta, S. K.; Melinamani, S.; Karmali, R.; Adeimy, C.; Smith, S.; Dalal, N.; Nabhan, C.; Peace, D.; Vose, J.; Evens, A. M.; Shah, N.; Fenske, T.; Zelenetz, A. D.; Landsburg, D. J.; Howlett, C.; Mato, A.; Jaglal, M.; Chavez, J. C.; Tsai, J. P.; Reddy, N.; Li, S.; Handler, C.; Flowers, C. R.; Cohen, J. B.; Blum, K. A.; Song, K.; Sun, H. L.; Press, O.; Cassaday, R.; Jaso, J.; Medeiros, L. J.; Sohani, A. R.; Abramson, J. S. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis.Blood (2014) 124:2354-2361. 25161267; 10.1182/blood-2014-05-578963
Petrich, A. M.; Nabhan, C.; Smith, S. M. MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches.Cancer (2014) 120:3884-3895. 25060588; 10.1002/cncr.28899
Petrich, A. M.; Rosen, S. T. Peripheral T-cell lymphoma: new therapeutic strategies.Oncology (Williston Park) (2013) 27:878-884. 24282984
Trifilio, S.; Ma, S.; Petrich, A. Reduced-dose carboxypeptidase-G2 successfully lowers elevated methotrexate levels in an adult with acute methotrexate-induced renal failure.Clin Adv Hematol Oncol (2013) 11:322-323. 23880719
Bayraktar, U. D.; Ramos, J. C.; Petrich, A.; Gupta, N.; Lensing, S.; Moore, P. C.; Reid, E. G.; Aboulafia, D. M.; Ratner, L.; Mitsuyasu, R.; Cooley, T.; Henry, D. H.; Barr, P.; Noy, A. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium.Leuk Lymphoma (2012) 53:2383-2389. 22642936; PMC3458169; 10.3109/10428194.2012.697559
Janakiram, M.; Thirukonda, V. K.; Sullivan, M.; Petrich, A. M. Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma.Curr Treat Options Oncol (2012) In process. 22297843; 10.1007/s11864-011-0178-9
Petrich, A. M.; Leshchenko, V.; Kuo, P. Y.; Xia, B.; Thirukonda, V. K.; Ulahannan, N.; Gordon, S.; Fazzari, M. J.; Ye, B. H.; Sparano, J. A.; Parekh, S. Akt Inhibitors MK-2206 and Nelfinavir overcome mTOR inhibitor resistance in DLBCL.Clin Cancer Res (2012) 18:2534-2544. 22338016; 10.1158/1078-0432.CCR-11-1407
Petrich, A. M.; Sparano, J. A.; Parekh, S. Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.Adv Hematol (2012) 2012:403648. 22570659; PMC3337598; 10.1155/2012/403648
Thirukonda, V.; Petrich, A.; Parekh, S. Classical Hodgkin lymphoma and spontaneous regression.Clin Adv Hematol Oncol (2012) 10:765-766. 23271267
Petrich, A.; Cho, S. I.; Billett, H. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns.Cancer (2011) 117:581-589. 20922788; 10.1002/cncr.25444
Yang, D. T.; Quann, P. J.; Petrich, A. M.; Leith, C. P.; Young, K. H.; Kahl, B. S. Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma.Appl Immunohistochem Mol Morphol (2011) 19:62-69. 20881841; PMC3040491; 10.1097/PAI.0b013e3181ed47bc
Leshchenko, V. V.; Kuo, P. Y.; Shaknovich, R.; Yang, D. T.; Gellen, T.; Petrich, A.; Yu, Y.; Remache, Y.; Weniger, M. A.; Rafiq, S.; Suh, K. S.; Goy, A.; Wilson, W.; Verma, A.; Braunschweig, I.; Muthusamy, N.; Kahl, B. S.; Byrd, J. C.; Wiestner, A.; Melnick, A.; Parekh, S. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma.Blood (2010) 116:1025-1034. 20427703; PMC2938124; 10.1182/blood-2009-12-257485
Petrich, A.; Kahl, B.; Bailey, H.; Kim, K.; Turman, N.; Juckett, M. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome.Leuk Lymphoma (2008) 49:57-61. 18203012; PMC2913589; 10.1080/10428190701713648

The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.


Co-Authors (14):

Similar Investigators (1):

Investigators you have not published with but by MeSH terms have significant overlap with your research

Keywords (MeSH):


Last updated from PubMed on Friday, September 04, 2015